WUXI APPTEC (02359) shares jumped more than 4% in morning trading, reaching a peak of 207 Hong Kong dollars and setting a new all-time high. As of the time of reporting, the stock was up 4.26% at 205.8 Hong Kong dollars, with a trading volume of 903 million Hong Kong dollars.

On August 7, the United States District Court for the District of Columbia granted WuXi Apptec's preliminary injunction motion, prohibiting the U.S. Department of Defense from enforcing the company's listing under Section 1260H during the litigation. This marks the first interim legal victory by a Chinese biopharmaceutical company challenging the U.S. military-linked list, providing confidence to global pharmaceutical clients and supply chains, as well as ensuring smooth delivery of new contracts for Chinese CDMO enterprises.

Meanwhile, WuXi Apptec has significantly raised its full-year 2026 performance guidance. Full-year revenue has been increased from 51.3 to 53.0 billion yuan to 58.5 to 60.5 billion yuan, with the growth rate for continuing operations boosted sharply from 18% to 22% up to 35% to 39%. The company is also accelerating its global capacity expansion, raising capital expenditure from 6.5 to 7.5 billion yuan to 7.5 to 8.5 billion yuan, and adjusted free cash flow from 10.5 to 11.5 billion yuan up to 13.5 to 14.5 billion yuan. The guidance upgrade spans revenue, profit, and cash flow across all three lines.